Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

myRocky vs OurView Health

myRocky
Graded #487

Lower grade

vs+16.199999999999996
OurView Health
Graded #162

Higher grade

The verdict

OurView Health takes it — 67.6/100 to 51.4/100.

OurView Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOurView Health +42
34
76
Dose & formulationOurView Health +11
53
64
Clinical oversightOurView Health +15
64
79
Labs & monitoringOurView Health +1
52
53
FulfillmentEven
70
70
Contract termsOurView Health +4
41
45
myRocky · left barOurView Health · right bar

The numbers

MetricmyRockyOurView Health
WeighScore51.4/10067.6/100
GradeCC
Scorecard rank#487#162
SemaglutideNot disclosed$75/mo (starting dose, compounded)
TirzepatideNot disclosed$135/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
OurView Health

Graded #162 · C

Strengths

  • Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
  • Clear product pricing with no contracts; medication shipped to your door (30-day supply)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
  • Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)

Where it loses points

  • A comparison table on the site quotes $90 'without membership' against $75 'with membership' while the product cards say 'No membership' and the cart charges $75 without one — the provider contradicts itself on whether a membership exists
  • Both figures are starting-dose rates; the cost of a titrated dose is published as a ladder rather than a single price
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard